141 related articles for article (PubMed ID: 32355741)
1. Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab.
Tamura R; Tanaka T; Morimoto Y; Kuranari Y; Yamamoto Y; Takei J; Murayama Y; Yoshida K; Sasaki H
Ann Transl Med; 2020 Mar; 8(6):297. PubMed ID: 32355741
[TBL] [Abstract][Full Text] [Related]
2. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.
Tamura R; Tanaka T; Ohara K; Miyake K; Morimoto Y; Yamamoto Y; Kanai R; Akasaki Y; Murayama Y; Tamiya T; Yoshida K; Sasaki H
Cancer Sci; 2019 Feb; 110(2):499-508. PubMed ID: 30467920
[TBL] [Abstract][Full Text] [Related]
3.
Suzuki T; Takei J; Fukasawa N; Suzuki K; Ogawa D; Yamamoto Y; Akasaki Y; Murayama Y; Shimoda M; Miyake K; Tanaka T
World Neurosurg; 2023 Jul; 175():e1364-e1374. PubMed ID: 37187346
[TBL] [Abstract][Full Text] [Related]
4. Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.
Thomas AA; Fisher JL; Hampton TH; Christensen BC; Tsongalis GJ; Rahme GJ; Whipple CA; Steel SE; Davis MC; Gaur AB; Lewis LD; Ernstoff MS; Fadul CE
Cancer Immunol Immunother; 2017 Mar; 66(3):379-389. PubMed ID: 27942839
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
6. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.
Tamura R; Morimoto Y; Sato M; Kuranari Y; Oishi Y; Kosugi K; Yoshida K; Toda M
J Neurooncol; 2020 Jan; 146(2):265-273. PubMed ID: 31897926
[TBL] [Abstract][Full Text] [Related]
7. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Shields LB; Kadner R; Vitaz TW; Spalding AC
Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
[TBL] [Abstract][Full Text] [Related]
8. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
[TBL] [Abstract][Full Text] [Related]
10. Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas.
Takei J; Fukasawa N; Tanaka T; Yamamoto Y; Tamura R; Sasaki H; Akasaki Y; Kamata Y; Murahashi M; Shimoda M; Murayama Y
Front Oncol; 2022; 12():898614. PubMed ID: 35785200
[TBL] [Abstract][Full Text] [Related]
11. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Zhu P; Du XL; Lu G; Zhu JJ
Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795
[TBL] [Abstract][Full Text] [Related]
13. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
[TBL] [Abstract][Full Text] [Related]
14. The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas.
Grossman R; Rudek MA; Brastianos H; Zadnik P; Brem H; Tyler B; Blakeley JO
Cancer Chemother Pharmacol; 2012 Jul; 70(1):129-39. PubMed ID: 22644796
[TBL] [Abstract][Full Text] [Related]
15. Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
Tamura R; Morimoto Y; Kosugi K; Sato M; Oishi Y; Ueda R; Kikuchi R; Nagashima H; Hikichi T; Noji S; Kawakami Y; Sasaki H; Yoshida K; Toda M
BMC Cancer; 2020 Mar; 20(1):196. PubMed ID: 32164575
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy, Temozolomide, and Antiprogrammed Cell Death Protein 1 Treatments Modulate the Immune Microenvironment in Experimental High-Grade Glioma.
Riva M; Wouters R; Sterpin E; Giovannoni R; Boon L; Himmelreich U; Gsell W; Van Ranst M; Coosemans A
Neurosurgery; 2021 Jan; 88(2):E205-E215. PubMed ID: 33289503
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
[TBL] [Abstract][Full Text] [Related]
18. Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Grossman R; Brastianos H; Blakeley JO; Mangraviti A; Lal B; Zadnik P; Hwang L; Wicks RT; Goodwin RC; Brem H; Tyler B
J Neurooncol; 2014 Jan; 116(1):59-65. PubMed ID: 24185441
[TBL] [Abstract][Full Text] [Related]
19. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
Grill J; Massimino M; Bouffet E; Azizi AA; McCowage G; Cañete A; Saran F; Le Deley MC; Varlet P; Morgan PS; Jaspan T; Jones C; Giangaspero F; Smith H; Garcia J; Elze MC; Rousseau RF; Abrey L; Hargrave D; Vassal G
J Clin Oncol; 2018 Apr; 36(10):951-958. PubMed ID: 29412784
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]